IM Cannabis (IMCC) Income from Continuing Operations (2020 - 2026)
IM Cannabis' (IMCC) quarterly Income from Continuing Operations came in at 1828847.88 in Q1 2026, down 1897.4% year-on-year from 101749.81 in Q1 2025, and up 67.58% quarter-over-quarter from 5640600.7 in Q4 2025.
IM Cannabis (IMCC) Income from Continuing Operations (2020 - 2026) Analysis & Trends
IM Cannabis' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 1828847.88 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 1897.4% year-over-year to 1828847.88 in Q1 2026; TTM through Mar 2026 was 10415739.95, a 203.59% decrease from a year earlier, with the FY2025 full-year figure at 8425763.83, down 6.27% from the prior year.
- Income from Continuing Operations rose to 1828847.88 in Q1 2026 per IMCC's latest filing, from 5640600.7 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3162061.52 in Q3 2022 and bottomed at 31126435.92 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 2526821.73 (2024), against an average of 4073777.27.
- Across the five-year window, Income from Continuing Operations jumped 379.57% in 2022 and sank 2553.06% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 31126435.92 in 2022, then surged by 60.03% to 12440093.69 in 2023, then jumped by 98.29% to 212607.19 in 2024, then sank by 2553.06% to 5640600.7 in 2025, then surged by 67.58% to 1828847.88 in 2026.
- Per Business Quant, the three latest IMCC Income from Continuing Operations figures stand at 1828847.88 (Q1 2026), 5640600.7 (Q4 2025), and 2808444.29 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | -1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.83 Mn |
| Dec 31, 2025 | -5.64 Mn |
| Sep 30, 2025 | -2.81 Mn |
| Jun 30, 2025 | -137,847.09 |
| Mar 31, 2025 | 101,749.81 |
| Dec 31, 2024 | -212,607.19 |
| Sep 30, 2024 | -793,163.79 |
| Jun 30, 2024 | -2.53 Mn |
| Mar 31, 2024 | -4.55 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | -2.88 Mn |
| Mar 31, 2023 | -652,412.19 |
| Dec 31, 2022 | -31.13 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | -2.77 Mn |
| Mar 31, 2022 | -5.75 Mn |
| Dec 31, 2021 | -6.63 Mn |
| Sep 30, 2021 | 659,359.73 |
| Jun 30, 2021 | -4.14 Mn |